Diversified Trust Co Sells 6,908 Shares of AbbVie Inc. $ABBV

Diversified Trust Co reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 10.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,257 shares of the company’s stock after selling 6,908 shares during the quarter. Diversified Trust Co’s holdings in AbbVie were worth $16,024,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ABBV. State Street Corp lifted its holdings in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. Fisher Asset Management LLC boosted its position in AbbVie by 252.6% in the 3rd quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock valued at $8,760,498,000 after buying an additional 23,991,451 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of AbbVie in the 2nd quarter valued at $2,905,952,000. Finally, Deutsche Bank AG increased its stake in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after buying an additional 1,241,587 shares during the period. 70.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent research reports. BNP Paribas Exane boosted their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Barclays raised their price target on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a report on Wednesday, October 21st. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Piper Sandler lifted their price objective on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Finally, Scotiabank boosted their price objective on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $297.46.

Trending Headlines about AbbVie

Investors following ABBV have been watching these headlines:

• Positive Sentiment: AbbVie reported positive Phase 3 results for QULIPTA in a migraine trial, a potential boost to its neuroscience portfolio and the drug’s growth prospects. AbbVie Reports Positive Phase 3 QULIPTA Migraine Trial Results
• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

AbbVie Stock Performance

Shares of ABBV stock opened at $295.18 on Friday. The firm’s 50 day moving average price is $275.51 and its two-hundred day moving average price is $240.91. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $302.93. The stock has a market cap of $521.76 billion, a PE ratio of 50.81, a PEG ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.86 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a $1.82 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio is currently 125.30%.

Insider Buying and Selling

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.